Delivery Order SPE2DB20D3111-SPE2DB25FA7NA
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $15,404.48 to AmerisourceBergen Drug Corp for the supply of Jardiance 10 mg tablets (90-count units) on July 31, 2025, with an ultimate completion date of August 1, 2025. This non-competitive delivery order utilizes firm fixed pricing and is sourced from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement to support federal healthcare operations....
- The Defense Logistics Agency awarded a delivery order valued at $29,882.35 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count) on November 14, 2025, with completion scheduled for November 17, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $22,670.24 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units) on June 12, 2025, with a completion date of June 13, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and designates AmerisourceBergen's Conshohocken, Pennsylvania location as the place of performance. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order valued at $23,151.22 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units) under a firm fixed-price contract. The award was made on May 20, 2025, with an ultimate completion date of May 21, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal military and veteran healthcare...
- The Defense Logistics Agency awarded a $15,577.62 delivery order to AmerisourceBergen Drug Corp on June 20, 2025, for the supply of Jardiance 10 mg tablets (90-count units). This is a firm fixed price, non-set-aside contract with a completion date of June 23, 2025, and performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $3,170.28 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units) under a firm fixed-price contract. The award was made on April 23, 2025, with an ultimate completion date of April 24, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this transaction. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Jardiance 25 mg tablets (90-count packaging) valued at $6,733.04 under a firm fixed-price contract. This non-set-aside delivery order is scheduled for completion by October 24, 2025, and will be fulfilled from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a single delivery order against AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Jardiance 25 mg tablets (90-count) valued at $5,638.65. This competitively awarded, firm fixed-price delivery order is set to be completed by August 8, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $35,131.14 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units) on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order represents a direct supply of the diabetes medication to support federal medical procurement needs. The contract was competitively awarded with no set-aside designation, and performance will be executed from AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $17,796.50 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count packages) on July 21, 2025, with an ultimate completion date of July 22, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at...
- SPE2DB20D3111Indefinite Delivery Contract
- SPE2DB20D3111-SPE2DB25FA7NADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $14,928.46 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units) on April 24, 2025, with an ultimate completion date of April 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support mechanism for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement through the Defense Logistics Agency's Medical Supply Chain. The company's role under this delivery order involves supplying diabetes medication to support military and veteran healthcare systems. This award is characteristic of AmerisourceBergen's extensive federal contract portfolio, which encompasses brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains, with the DLA planning to establish additional Pharmaceutical Prime Vendor Global Program Generation V contracts involving multiple regional awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.9k | 4/24/25 |